Study Summary
This trial will test how well azacitidine works in treating people with MDS.
- Myelodysplastic Syndrome
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
3 Primary · 25 Secondary · Reporting Duration: Up to 5 years after discontinuation of Investigational Product, approximately 6 years
Trial Safety
Phase-Based Safety
Trial Design
4 Treatment Groups
Part II - Oral-Aza (RP3D)
1 of 4
Part I - Oral-Aza (Dose 2)
1 of 4
Part II - Placebo
1 of 4
Part I - Oral-Aza (Dose 1)
1 of 4
Experimental Treatment
230 Total Participants · 4 Treatment Groups
Primary Treatment: Oral Azacitidine · Has Placebo Group · Phase 2 & 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What aim does this particular clinical trial have?
"The aim of this trial, which will run for 24 weeks, is to see the number of participants who achieve remission as defined by the 2006 IWG criteria. Other measures of success include secondary outcomes like CR and OR duration (both in Phase 2 and 3) as well as Number of participants who become platelet transfusion independent within 6 cycles." - Anonymous Online Contributor
In how many places can patients sign up for this trial?
"7 sites are running this clinical trial, which are situated in locations including Portland, Charlotte and East Syracuse. To reduce the amount of travel needed, patients are encouraged to select the site closest to their location." - Anonymous Online Contributor